AU2001263992A1 - Method for in vitro diagnosis of prostatic cancer and kit therefor - Google Patents

Method for in vitro diagnosis of prostatic cancer and kit therefor

Info

Publication number
AU2001263992A1
AU2001263992A1 AU2001263992A AU6399201A AU2001263992A1 AU 2001263992 A1 AU2001263992 A1 AU 2001263992A1 AU 2001263992 A AU2001263992 A AU 2001263992A AU 6399201 A AU6399201 A AU 6399201A AU 2001263992 A1 AU2001263992 A1 AU 2001263992A1
Authority
AU
Australia
Prior art keywords
vitro diagnosis
kit
prostatic cancer
prostatic
kit therefor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001263992A
Inventor
Karine Chantrel-Groussard
Olivier Cussenot
Alain Latil
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Urogene SA
Original Assignee
Urogene SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Urogene SA filed Critical Urogene SA
Publication of AU2001263992A1 publication Critical patent/AU2001263992A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)

Abstract

The invention concerns a novel method for in vitro diagnosis and/or prognosis of prostatic cancer from a cell sample of prostatic origin non-invasively collected in urine or slightly invasively via a biopsy needle. The method consists in looking for chromosomal alterations detected by allelic losses, from DNA extracts of cells of prostatic origin, on at least one chromosomal region. The invention also concerns a kit for implementing said method and the use of such a kit for feeding a database assembling patients' phenotypic and genotypic data, and for monitoring an anticancer treatment.
AU2001263992A 2000-06-27 2001-05-22 Method for in vitro diagnosis of prostatic cancer and kit therefor Abandoned AU2001263992A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0008266 2000-06-27
FR0008266A FR2810677B1 (en) 2000-06-27 2000-06-27 PROCESS FOR IN VITRO DIAGNOSIS OF PROSTATE CANCER AND IMPLEMENTATION KIT
PCT/FR2001/001566 WO2002000929A1 (en) 2000-06-27 2001-05-22 Method for in vitro diagnosis of prostatic cancer and kit therefor

Publications (1)

Publication Number Publication Date
AU2001263992A1 true AU2001263992A1 (en) 2002-01-08

Family

ID=8851762

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001263992A Abandoned AU2001263992A1 (en) 2000-06-27 2001-05-22 Method for in vitro diagnosis of prostatic cancer and kit therefor

Country Status (6)

Country Link
EP (1) EP1294941B1 (en)
AT (1) ATE286541T1 (en)
AU (1) AU2001263992A1 (en)
DE (1) DE60108245D1 (en)
FR (1) FR2810677B1 (en)
WO (1) WO2002000929A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1510587B1 (en) * 2002-05-21 2011-07-13 Sysmex Corporation Nucleic acid amplification primers for detecting cytokeratins and examination method with the use of the primers
FR2849382A1 (en) * 2002-12-26 2004-07-02 Urogene USE OF THE HTR2B GENE FOR THE TREATMENT OF PROSTATE CANCER
IL172297A (en) 2005-10-03 2016-03-31 Compugen Ltd Soluble vegfr-1 variants for diagnosis of preeclamsia
WO2008039774A1 (en) 2006-09-25 2008-04-03 Mayo Foundation For Medical Education And Research Extracellular and membrane-associated prostate cancer markers
US8338109B2 (en) 2006-11-02 2012-12-25 Mayo Foundation For Medical Education And Research Predicting cancer outcome
AU2009253675A1 (en) 2008-05-28 2009-12-03 Genomedx Biosciences, Inc. Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer
US10407731B2 (en) 2008-05-30 2019-09-10 Mayo Foundation For Medical Education And Research Biomarker panels for predicting prostate cancer outcomes
FR2981662A1 (en) * 2011-10-20 2013-04-26 Assist Publ Hopitaux De Paris METHOD OF QUANTIFYING RENAL MARKERS BY URINARY DOSAGE.
AU2012352153B2 (en) 2011-12-13 2018-07-26 Veracyte, Inc. Cancer diagnostics using non-coding transcripts
EP4219765A3 (en) 2012-08-16 2023-09-20 Decipher Biosciences, Inc. Prostate cancer prognosis using biomarkers
WO2018039490A1 (en) 2016-08-24 2018-03-01 Genomedx Biosciences, Inc. Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy
US11208697B2 (en) 2017-01-20 2021-12-28 Decipher Biosciences, Inc. Molecular subtyping, prognosis, and treatment of bladder cancer
EP3593140A4 (en) 2017-03-09 2021-01-06 Decipher Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
CA3062716A1 (en) 2017-05-12 2018-11-15 Decipher Biosciences, Inc. Genetic signatures to predict prostate cancer metastasis and identify tumor agressiveness
CN113025721A (en) * 2021-04-28 2021-06-25 苏州宏元生物科技有限公司 Prostate cancer diagnosis and prognosis evaluation kit

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7640494A (en) * 1993-09-03 1995-03-22 Cellpro, Incorporated Methods for quantifying the number of cells containing a selected nucleic acid sequence in a heterogenous population of cells
EP0859860A1 (en) * 1995-10-23 1998-08-26 Imperial Cancer Research Technology Limited Diagnosis of susceptibility to cancer and treatment thereof
US6479263B1 (en) * 1996-11-14 2002-11-12 Baylor College Of Medicine Method for detection of micrometastatic prostate cancer
US6140049A (en) * 1996-11-21 2000-10-31 Genset Detection and early diagnosis of prostate cancer
JPH10276780A (en) * 1997-04-01 1998-10-20 Sumitomo Metal Ind Ltd Detection of psa mrna and detection kit
US6200765B1 (en) * 1998-05-04 2001-03-13 Pacific Northwest Cancer Foundation Non-invasive methods to detect prostate cancer

Also Published As

Publication number Publication date
EP1294941B1 (en) 2005-01-05
WO2002000929A1 (en) 2002-01-03
FR2810677B1 (en) 2004-10-01
FR2810677A1 (en) 2001-12-28
DE60108245D1 (en) 2005-02-10
ATE286541T1 (en) 2005-01-15
EP1294941A1 (en) 2003-03-26

Similar Documents

Publication Publication Date Title
AU2001263992A1 (en) Method for in vitro diagnosis of prostatic cancer and kit therefor
MXPA03003281A (en) Non-invasive enzyme screen for tissue remodelling-associated conditions.
WO2000052204A3 (en) Gene expression in bladder tumors
WO2006094032A3 (en) Guiding differential diagnosis through information maximization
AU4694499A (en) Trace level detection of analytes using artificial olfactometry
WO2001036972A3 (en) Elisa for vegf
WO2002024956A3 (en) Genetic markers for tumors
WO2004032621A3 (en) Techniques for identifying molecular structures and treating cell types lining a body lumen using fluorescence
WO2004086949A3 (en) Dna markers for management of cancer
WO2006060265A3 (en) Methods and systems for prognosis and treatment of solid tumors
IL146125A0 (en) Novel quinones as disease therapies
EP1135531A4 (en) Methods for introducing heterologous cells into fish
WO2002077176A3 (en) Aberrantly expressed proteins in laser capture microdissected tumors
WO2000070340A3 (en) Materials and methods relating to disease diagnosis
WO2003030725A3 (en) Pancreatic cancer diagnosis and therapies
WO2001092877A3 (en) Method of identifying and/or isolating stem cells
WO2002076286A3 (en) Prognostic methods for breast cancer
WO2000058509A3 (en) Prostate cancer associated human fibronectin gene and biallelic markers
Wolff et al. Second malignancies in melanoma patients in Thuringia
FI943355A (en) A method for assessing the likelihood of a particular cancer occurring in a patient
RS20060255A (en) Quick test for the diagnosis of alzheimer's disease
WO2004074514A3 (en) Method of diagnosis of type 2 diabetes and early onset thereof
AU2002348101A1 (en) Ibc-1 (invasive breast cancer-1), a putative oncogene amplified in breast cancer
Fee et al. De Morbis Artificum Diatriba [Diseases of Workers].
AU4753900A (en) Methods of diagnosing or treating alzheimer's disease